

For more information on the trials listed here, please call PDQ, a service of the National Cancer Institute, at 1-800-4-CANCER. The PDQ Web site is accessible at [www.cancer.gov/clinical\\_trials](http://www.cancer.gov/clinical_trials). A searchable Web site developed by the National Library of Medicine is also available at <http://clinicaltrials.gov>.

## Phase III

### **Phase III High-Dose Interferon alfa in Treating Patients With Stage II or Stage III Melanoma**

ECOG-1697, NCT00003641, CALGB-500103, CAN-NCIC-ME.10, COG-E1697, SWOG-E1697

### **Phase III Vaccine Therapy and/or Sargramostim in Treating Patients With Locally Advanced or Metastatic Melanoma**

ECOG-4697, NCT00005034, SWOG-E4697

### **Phase III Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma**

SWOG-S0008, NCT00006237, CALGB-500002, COG-S0008, ECOG-S0008

### **Phase III MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Melanoma**

MDX010-20, NCT00094653

### **Phase III Carboplatin and Paclitaxel With or Without Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Melanoma**

ECOG-E2603, NCT00110019, SWOG-E2603

## Phase II

### **Phase II Bevacizumab With or Without Interferon alfa in Treating Patients With Metastatic Malignant Melanoma**

OSU-01H0185, NCT00026221, NCI-2669

### **Phase II Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma**

MDA-2003-0988, NCT00082875, NCI-6387

### **Phase II Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer**

NCI-04-C-0134

### **Phase II Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery**

SWOG-S0508, NCT00104988

### **Phase II Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Melanoma**

A4061015, NCT00094107

### **Phase II Sorafenib in Treating Patients With Stage IV Melanoma**

NYWCCC-NYU-0438, NCT00119249, NCI-6617

### **Phase II Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic or Unresectable Melanoma**

PMH-PHL-040, NCI-6916

### **Phase II Study of Vaccine Therapy Comprising Autologous Tumor Cells and a Sargramostim (GM-CSF)-Producing and CD40L-Expressing Cell Line (GM.CD40L) in Patients With Stage IIIC or IV Malignant Melanoma**

MCC-13639, MCC-102781, NCT00101166

## Phase I/II

### **Phase I/II Cyclophosphamide and Fludarabine Followed by Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma**

NCI-03-C-0162, NCT00059163, NCI-5855

## Phase I

### **Phase I CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery**

UCLA-0312023, PFIZER-NRA3670003, NCT00090896

---

The trials below are currently being conducted at Moffitt Cancer Center. For additional information about these trials, please call the Clinical Trials Office at (813) 972-8352 or e-mail Patricia Urbas at [urbaspa@moffitt.usf.edu](mailto:urbaspa@moffitt.usf.edu).

**Phase III Randomized Study of Four Weeks High-Dose IFN- $\alpha$ 2B in Stage T3-T4 or N1 (microscopic) Melanoma**

Protocol #: 11990

**Phase III Study of Taxoprexin Injection vs Dacarbazine in Patients With Metastatic Malignant Melanoma**

Protocol #: 13794

**Multicenter Selective Lymphadenectomy for Melanoma Trial II: A Phase II Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node**

Protocol #: 14120

**A Phase II Trial Using a Universal GM-CSF-Producing and CD40L Expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-Based Vaccines in Patients With Melanoma**

Protocol #: 13639

**A Phase II Trial of GM-CSF in Patients With High-Risk Melanoma**

Protocol #: 13690

**Phase I/II Trial of Valproic Acid and Karenitecin in Metastatic Malignant Melanoma**

Protocol #: 13991

**Phase I Trial of Intratumoral IL-12 Electroporation in Malignant Melanoma**

Protocol #: 13224

**Phase I Open Label, Non-Randomized, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immune Function Effects, and Efficacy of Multiple Doses of CP-675-206 in Patients With Advanced Melanoma, and Phase 2, Open Label, Randomized Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of 2 Regimens of CP-675,206 in Patients With Advanced Melanoma**

Protocol #: 13728

**Molecular Signatures of Src and STAT3 Signaling in Patients With Melanoma**

Protocol #: 14132

**Serial Biopsy of Malignant Melanoma to Assess Predictors of Response**

Protocol #: 12897